View Exam | PowerPak

1. What term best describes the mechanism of action and synergistic effect of PARP inhibitors on DNA repair in patients with BRCA mutations?

A. Homologous repair deficiency B. Synthetic lethality C. PARP trapping D. Gene targeting E. Unsure

2. What is the mechanism of serum creatinine increase with olaparib and rucaparib?

A. Inhibition of MATE transporters B. Renal tubule damage C. Tubular necrosis D. Nephrotic syndrome E. Unsure

3. Which of the following is a recommended antiemetic regimen for olaparib?

A. Ondansetron 4-8 mg with each olaparib dose (8-16 mg/day) B. Palonosetron 0.25 mg and dexamethasone 8 mg on Day 1 C. Prochlorperazine 5-10 mg every 6 hours as needed D. Prochlorperazine 5-10 mg with each olaparib dose (10-20 mg/day) E. Unsure

4. SB is a 67-year-old woman with ovarian cancer. She was treated with 3 cycles of neoadjuvant carboplatin and paclitaxel followed by optimal debulking surgery. Genetic risk evaluation reveals that she does not have a BRCA mutation but is homologous repair deficient. Which PARP inhibitor (or inhibitors) has phase III trials to support its use in the first-line maintenance setting in newly diagnosed ovarian cancer?

A. Olaparib B. Niraparib C. Olaparib and niraparib D. Olaparib, niraparib, and rucaparib E. Unsure

5. GB is a 77-year-old woman with platinum-sensitive, recurrent ovarian cancer. She received 6 cycles of carboplatin and liposomal doxorubicin with a plan to continue therapy with niraparib maintenance. What factors should be taken into account when selecting her initial dose?

A. Age and performance status B. Platelet count and weight C. Platelet count, weight, and age D. Age and weight E. Unsure

Evaluation Questions

6. How confident are in your treatment choice for patient SB in the post-test?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. What term best describes the mechanism of action and synergistic effect of PARP inhibitors on DNA repair in patients with BRCA mutations?

2. What is the mechanism of serum creatinine increase with olaparib and rucaparib?

3. Which of the following is a recommended antiemetic regimen for olaparib?

5. GB is a 77-year-old woman with platinum-sensitive, recurrent ovarian cancer. She received 6 cycles of carboplatin and liposomal doxorubicin with a plan to continue therapy with niraparib maintenance. What factors should be taken into account when selecting her initial dose?

Evaluation Questions

6. How confident are in your treatment choice for patient SB in the post-test?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. What term best describes the mechanism of action and synergistic effect of PARP inhibitors on DNA repair in patients with BRCA mutations?

2. What is the mechanism of serum creatinine increase with olaparib and rucaparib?

3. Which of the following is a recommended antiemetic regimen for olaparib?

5. GB is a 77-year-old woman with platinum-sensitive, recurrent ovarian cancer. She received 6 cycles of carboplatin and liposomal doxorubicin with a plan to continue therapy with niraparib maintenance. What factors should be taken into account when selecting her initial dose?

Evaluation Questions

6. How confident are in your treatment choice for patient SB in the post-test?

« Return to Activity

Customers who Purchased
this Activity also Purchased